Bio Financial Statements From 2010 to 2024

BPTH Stock  USD 0.80  0.02  2.44%   
Bio Path financial statements provide useful quarterly and yearly information to potential Bio Path Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bio Path financial statements helps investors assess Bio Path's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bio Path's valuation are summarized below:
Market Capitalization
3.5 M
Earnings Share
(8.34)
We have found one hundred twenty available fundamental signals for Bio Path Holdings, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Bio Path Holdings prevailing fundamentals against the fundamentals between 2010 and 2024 to make sure the company is sustainable this year.

Bio Path Total Revenue

37,000

Check Bio Path financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Path's main balance sheet or income statement drivers, such as Depreciation And Amortization of 77.9 K, Interest Expense of 31.2 K or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 472, Dividend Yield of 0.0 or PTB Ratio of 10.54. Bio financial statements analysis is a perfect complement when working with Bio Path Valuation or Volatility modules.
  
Check out the analysis of Bio Path Correlation against competitors.

Bio Path Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.1 M3.2 M9.9 M
Slightly volatile
Short and Long Term Debt Total175.6 K113 K333.7 K
Slightly volatile
Other Current Liabilities1.3 M1.2 M641.1 K
Slightly volatile
Total Current LiabilitiesM1.9 M967.4 K
Slightly volatile
Property Plant And Equipment Net344.7 K178 K319.4 K
Slightly volatile
Current Deferred Revenue10.3 K10.8 K12.9 K
Slightly volatile
Accounts Payable479.9 K457 K244.9 K
Slightly volatile
Cash999.4 K1.1 M7.6 M
Slightly volatile
Non Current Assets Total169.1 K178 K892 K
Slightly volatile
Cash And Short Term Investments999.4 K1.1 M7.6 M
Slightly volatile
Common Stock Shares Outstanding292.6 K478 K345.6 K
Pretty Stable
Liabilities And Stockholders Equity3.1 M3.2 M9.9 M
Slightly volatile
Non Current Liabilities Total916.6 K873 K460.7 K
Pretty Stable
Other Current Assets2.1 MM1.1 M
Slightly volatile
Other Stockholder Equity113.4 M108 M56.2 M
Slightly volatile
Total Liabilities2.9 M2.8 M1.3 M
Slightly volatile
Property Plant And Equipment Gross1.3 M1.2 M573.9 K
Slightly volatile
Total Current Assets2.9 MMM
Slightly volatile
Short Term Debt172.6 K206 K121.1 K
Slightly volatile
Intangible Assets1.3 M692.1 K1.2 M
Slightly volatile
Common Stock950100037.3 K
Slightly volatile
Common Stock Total Equity4.3 K4.5 K37.5 K
Slightly volatile
Capital Surpluse99.4 M94.6 M52.3 M
Slightly volatile
Other Liabilities2.3 M2.6 M2.8 M
Slightly volatile
Net Invested Capital418.9 K441 K9.5 M
Very volatile
Net Working Capital1.1 M1.1 M8.7 M
Pretty Stable
Capital Stock95010002.3 K
Slightly volatile
Capital Lease Obligations210.2 K113 K350.6 K
Slightly volatile

Bio Path Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization77.9 K82 K190.3 K
Very volatile
Selling General Administrative2.4 M4.2 M2.9 M
Slightly volatile
Other Operating Expenses16.6 M15.8 MM
Slightly volatile
Total Operating Expenses16.6 M15.8 MM
Slightly volatile
Research Development12.2 M11.6 MM
Slightly volatile
Non Operating Income Net Other28.4 K29.9 K263.5 K
Very volatile
Interest Income31 K52 K24.9 K
Slightly volatile
Net Interest Income32.5 K52 K22.7 K
Slightly volatile
Preferred Stock And Other Adjustments830.4 K934.2 KM
Slightly volatile
Reconciled Depreciation198.9 K183 K321.1 K
Slightly volatile
Non Recurring486.4 K547.2 K595.8 K
Slightly volatile
Selling And Marketing Expenses98.4 K110.7 K120.5 K
Slightly volatile

Bio Path Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow6.1 M10.4 M7.9 M
Slightly volatile
Depreciation179.9 K204.7 K205.3 K
Pretty Stable
Total Cash From Financing Activities2.1 M2.2 MM
Pretty Stable
End Period Cash Flow999.4 K1.1 M7.6 M
Slightly volatile
Change Receivables195.6 K220 K239.6 K
Slightly volatile
Stock Based Compensation531.6 K734 K422.1 K
Slightly volatile
Issuance Of Capital Stock3.3 M3.4 M4.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4724974.1 K
Slightly volatile
Days Sales Outstanding56.4287.790.7354
Very volatile
Average Payables69 K97.9 K100.5 K
Very volatile
Stock Based Compensation To Revenue44.9624.6541.3572
Slightly volatile
Capex To Depreciation0.10.110.5833
Slightly volatile
EV To Sales3343513.8 K
Slightly volatile
Inventory Turnover89.0344.66219
Slightly volatile
Days Of Inventory On Hand8.048.4614.0422
Slightly volatile
Payables Turnover0.370.38951.9141
Slightly volatile
Sales General And Administrative To Revenue180110166
Slightly volatile
Average Inventory3.5 K2.1 K1.7 K
Very volatile
Research And Ddevelopement To Revenue313170288
Slightly volatile
Capex To Revenue13.7413.0913.4213
Slightly volatile
Cash Per Share2.092.2008155
Slightly volatile
Days Payables Outstanding984937443
Slightly volatile
Income Quality0.660.71740.8575
Slightly volatile
Intangibles To Total Assets0.09480.09980.2091
Slightly volatile
Current Ratio1.521.5969.7585
Pretty Stable
Receivables Turnover6.194.314.2076
Very volatile
Graham Number25.126.424718
Slightly volatile
Capex Per Share0.06310.06645.1542
Slightly volatile
Average Receivables115.5 K110 K113.5 K
Slightly volatile
Revenue Per Share1.61.691.8884
Slightly volatile
Interest Debt Per Share0.20.21552.6561
Slightly volatile
Debt To Assets0.03040.0320.0958
Slightly volatile
Days Of Payables Outstanding984937443
Slightly volatile
Ebt Per Ebit1.081.01480.9911
Pretty Stable
Total Debt To Capitalization0.180.18930.1552
Slightly volatile
Quick Ratio1.521.5969.7467
Pretty Stable
Net Income Per E B T1.11.151.0099
Slightly volatile
Cash Ratio0.520.55198.5649
Very volatile
Days Of Inventory Outstanding8.048.4614.0422
Slightly volatile
Days Of Sales Outstanding56.4287.790.7354
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.171.151.0483
Pretty Stable
Fixed Asset Turnover0.06180.06510.0943
Slightly volatile
Debt Ratio0.03040.0320.0958
Slightly volatile
Price Sales Ratio4724974.1 K
Slightly volatile
Asset Turnover0.00460.00480.0379
Slightly volatile
Operating Cycle198203222
Slightly volatile

Bio Path Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap18.4 M22.8 M23.8 M
Pretty Stable
Enterprise ValueM2.1 M5.5 M
Slightly volatile

Bio Fundamental Market Drivers

Cash And Short Term Investments1.1 M

Bio Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bio Path Financial Statements

Investors use fundamental indicators, such as Bio Path's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bio Path's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue10.8 K10.3 K
Cost Of Revenue204.7 K194.5 K
Stock Based Compensation To Revenue 24.65  44.96 
Sales General And Administrative To Revenue 109.50  179.88 
Research And Ddevelopement To Revenue 170.32  313.05 
Capex To Revenue 13.09  13.74 
Revenue Per Share 1.69  1.60 
Ebit Per Revenue(278.67)(292.61)

Currently Active Assets on Macroaxis

When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:
Check out the analysis of Bio Path Correlation against competitors.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.34)
Return On Assets
(1.40)
Return On Equity
(3.66)
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.